Archive

British American Tobacco: Fighting An Uphill Battle (Archive)

BTI’s value trap deepens as secular decline and illicit vapes overpower cheap valuation.

Alibaba: Nothing Has Changed To Make Buys Compelling (Archive)

Alibaba remains a value trap without clear sales or margin recovery catalysts yet.

Ares Capital: Competition Weighs Down On Yields And Margins (Archive)

Competitive pressures erode Ares Capital’s high-yield deal access and compress net investment margins.

Energy Transfer: Less Attractive For Fresh Buyers (Archive)

Valuation discounts have narrowed and technicals point to fading upside for incremental buyers.

Why NVIDIA Is Not Yet In Its Hype Cycle (Archive)

NVIDIA is growing in multiples, margins are soaring, and valuations still avoid true hype.

Super Micro Computer: The Time Correction Is Not Yet Over (Archive)

SMCI’s stellar AI-driven growth persists, but margins, ROICs, and valuation temper conviction.

Pfizer: Too Early For A Turnaround (Archive)

Pfizer’s oncology pivot and CEO incentives cloud the timing and quality of any turnaround.